OIA
CNCE

Optimum Investment Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Optimum Investment Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,500
Closed -$20K – 1005
2014
Q4 		$20K Hold
1,500
– – 0.01% 720
2014
Q3 		$19K Hold
1,500
– – 0.01% 659
2014
Q2 		$15K Buy
+1,500
New +$14.5K ﹤0.01% 715

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Optimum Investment Advisors's CNCE Position: Q1 2015 in Review

Optimum Investment Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2015, closing a stake of 1,500 shares — an estimated $20K sold.

Optimum Investment Advisors first reported a position in CNCE in Q2 2014 and held it in 3 quarters. The position peaked at $20K in Q4 2014. 68 funds tracked by Wall St. Rank hold CNCE as of Q1 2015.

  • Optimum Investment Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Optimum Investment Advisors sold 1,500 Concert Pharmaceuticals, Inc. shares in Q1 2015, an estimated $20K.
  • Optimum Investment Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 3 quarters.
  • Optimum Investment Advisors's Concert Pharmaceuticals, Inc. position peaked at $20K in Q4 2014.
  • 68 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2015.

Based on Optimum Investment Advisors's 13F filing for Q1 2015, filed 18 May 2015.